Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
ABC > SEC Filings for ABC > Form 8-K on 1-Apr-2013All Recent SEC Filings

Show all filings for AMERISOURCEBERGEN CORP | Request a Trial to NEW EDGAR Online Pro

Form 8-K for AMERISOURCEBERGEN CORP


1-Apr-2013

Regulation FD Disclosure, Other Events, Financial Statements and Exhibits


Item 7.01. Regulation FD Disclosure.

On March 28, 2013, AmerisourceBergen Corporation (the "Company") issued a news release in which it announced that it had revised its financial performance expectations for fiscal year 2013. The Company now expects revenue growth in the range of 8 to 10 percent and it has increased its estimated earnings per share from continuing operations for fiscal year 2013 from a range of $2.96 to $3.06 to a range of $3.04 to $3.14. The revised earnings per share range does not include the impact of significant one-time expenses anticipated as a result of the previously disclosed new strategic long-term relationship with Walgreen Co. and Alliance Boots, GmbH, including a LIFO expense due to an anticipated inventory build and recurring non-cash expenses relating to the equity warrants issued in connection with the new relationship. The Company continues to expect free cash flow in the range of $100 million to $200 million, and to repurchase approximately $400 million of common stock in fiscal year 2013.



Item 8.01. Other Events.

In the news release issued on March 28, 2013, the Company also announced that it had entered into a definitive agreement to sell its Canadian pharmaceutical distribution business, AmerisourceBergen Canada Corporation ("ABCC"), to Kohl & Frisch Limited, a Canadian-owned national full-line distributor. The estimated sale price is expected to be between $80 million and $100 million, of which approximately half will be financed by the Company. The transaction is subject to regulatory review and other customary closing conditions, and is expected to close in the third quarter of fiscal 2013.

As a result of the agreement, the Company expects to record an estimated loss on sale and other impairment charges of between $160 million and $180 million when it reports its quarterly results for the March quarter of fiscal 2013. This estimated loss on sale, in addition to ABCC's operating losses, will be reported within discontinued operations. ABCC represented approximately 2 percent of Company's total revenues.

The news release issued on March 28, 2013 is filed as Exhibit 99.1 to this report and is incorporated herein by reference.



Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

The following exhibits are filed as part of this report:

99.1 News Release, dated March 28, 2013, of AmerisourceBergen Corporation, regarding the entry into an agreement to sell its Canadian pharmaceutical distribution business.


  Add ABC to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for ABC - All Recent SEC Filings
Sign Up for a Free Trial to the NEW EDGAR Online Pro
Detailed SEC, Financial, Ownership and Offering Data on over 12,000 U.S. Public Companies.
Actionable and easy-to-use with searching, alerting, downloading and more.
Request a Trial      Sign Up Now


Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.